Overview

A Phase I, Open-label, Crossover Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults

Status:
NOT_YET_RECRUITING

Trial end date:
2026-05-25

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess how well laroprovstat and rosuvastatin combined in a single tablet to be taken by mouth works compared with laroprovstat and rosuvastatin individual tablets taken by mouth (relative bioavailability) in healthy adults.

Phase:

PHASE1

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Parexel